↓ Skip to main content

American Association for Cancer Research

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Overview of attention for article published in Molecular Cancer Therapeutics, December 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter
84 X users
patent
2 patents

Citations

dimensions_citation
83 Dimensions

Readers on

mendeley
53 Mendeley
Title
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Published in
Molecular Cancer Therapeutics, December 2019
DOI 10.1158/1535-7163.mct-18-1399
Pubmed ID
Authors

Paulo Bergerot, Peter Lamb, Evelyn Wang, Sumanta K Pal

X Demographics

X Demographics

The data shown below were collected from the profiles of 84 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 21%
Other 6 11%
Student > Bachelor 3 6%
Student > Doctoral Student 3 6%
Student > Postgraduate 3 6%
Other 8 15%
Unknown 19 36%
Readers by discipline Count As %
Medicine and Dentistry 13 25%
Biochemistry, Genetics and Molecular Biology 4 8%
Agricultural and Biological Sciences 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Unspecified 1 2%
Other 6 11%
Unknown 22 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2024.
All research outputs
#772,072
of 24,799,506 outputs
Outputs from Molecular Cancer Therapeutics
#82
of 4,011 outputs
Outputs of similar age
#18,737
of 470,981 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 91 outputs
Altmetric has tracked 24,799,506 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,011 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 470,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.